Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. - Wikidata - wikimedia - TriplyDB

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

http://www.wikidata.org/entity/Q37042128

about

Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis An evaluation of overall effectiveness and treatment satisfaction with intravenous immunoglobulin among patients with immune thrombocytopenia.Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects.Protective effects of PPARγ agonist in acute nephrotic syndrome.Limitations and future treatment options in type 2 diabetes with renal impairment.In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.PPARγ and chronic kidney disease.Pathogenesis and therapy of focal segmental glomerulosclerosis: an update.Impact of glomerular kidney diseases on the clearance of drugs.Mitochondrial dysfunction in the pathophysiology of renal diseases.Chronic kidney disease: targeting prostaglandin E2 receptors.Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.Peroxisome proliferator activating receptor-γ and the podocyte.Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies.

P2860

Q28285877-163BB669-89D0-444F-884A-D988DA0325DC Q33431970-739517F3-DBCC-4158-91B2-9AFE1B5580C8 Q33527568-254B69B3-0CB8-4D93-A6A5-848607539625 Q33584368-EDD78570-D911-416D-A9B6-2BB782953A80 Q33817568-2C366F7E-930B-4F78-A263-993C246E503E Q34260759-F0DC1F40-8858-4A7E-82B1-8DFA6A8F362D Q35188070-31B1C555-9E48-426D-8A5E-C1F2A407F707 Q35747241-F4F85F93-3D28-4347-A1C4-79C5FFAE9DBC Q36783886-9A6EAB12-AFC8-4510-BBA3-EE6DD220080A Q37622756-F2CB79CB-237D-48D0-820F-B01AE01575FD Q37777055-CC8513A8-F8A6-46A7-9E12-6C3753211565 Q37812564-5B72B2FA-E62F-4055-AB1A-705CA2FA7EF2 Q37974647-CCEB99D1-9AF4-4809-A26C-ACDDCC5BFD50 Q38168664-FFE3466A-06D9-40DD-86BC-5119142EF14E Q38223323-0654C558-A267-48E4-8E02-756922DFA9A7 Q38738516-A2745142-1719-4EF3-A902-2FF4FC7076EF Q38815188-204B5011-3964-4621-85F1-3E43242EBD20 Q44580484-A430BD5A-31D3-4E2B-8756-BA4F4C9B9DBE Q52674866-6D3AA90B-056D-4C58-9E25-4C8571616EAD

P2860

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

http://www.wikidata.org/entity/Q37042128

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

@en

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

@nl

type

label

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

@en

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

@nl

prefLabel

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

@en

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

@nl

P1433

Q37042128-156CCA74-49CF-42C9-A684-754210C9D42C

P1476

Q37042128-01250F78-5D5A-4C07-98EA-0802974D53AF

P2093

Q37042128-26298C82-48BC-439D-97C6-5B70A0A74E9C

Q37042128-3389ED99-38D3-4F58-AD54-978D54E8B6CB

Q37042128-48D34783-82BF-4457-9204-A2968EF3644E

Q37042128-5CE3D6EC-4846-4A52-BD83-AA8DFDA94530

Q37042128-5FB47B5C-77E6-4308-B244-1FD643FC5DEB

Q37042128-AF204A60-3D43-4DFC-B0B6-1C66746C1530

Q37042128-C280A739-68A6-4382-80EB-C074B7874ACC

Q37042128-FF857A28-30FA-4E1B-9205-D06F4678DD0C

P2860

Q37042128-019AC2D6-DE8E-4954-B5C0-2039EAA558D1

Q37042128-0B25AFC5-2999-4692-8658-EB7B9F012E2A

Q37042128-1E42E874-E3D5-435C-9318-F8DBA0D44D7F

Q37042128-33223372-B095-498A-BE4F-1DD819430F95

Q37042128-384FEA1F-915C-48DF-A1AD-24D1C4231CDA

Q37042128-3D09853E-94B3-44F4-9A2B-6B4770ABE1C0

Q37042128-61C97847-A1E3-4EFF-B25B-FDC64D217E56

Q37042128-69C4C668-5F33-4FB6-9128-83A47F3F231A

Q37042128-716B98A8-FEF7-4480-A437-8E84833862C4

Q37042128-7C42B466-113A-4AE6-9CE1-E980B3CC8165

P304

Q37042128-09EFD765-C496-4C2C-AC58-DFE186E79422

P31

Q37042128-F91CF5E7-6059-4868-8E39-903281EA6C62

P356

Q37042128-A798041C-55F0-4F86-8031-69C8C55153DB

P433

Q37042128-84FCE1FE-2620-42E7-8929-6066C046FCD8

P478

Q37042128-854FF8EC-3B64-4205-8BEA-DBB76A7038CE

P50

Q37042128-5465F83E-A5DA-49B4-B9D1-8794B516B3CC

Q37042128-70C9699F-DF1B-4286-91B7-8C220CD92EA9

Q37042128-C1FE0514-7EB5-44FA-9E22-D50512B3EA26

P577

Q37042128-CC48A74C-1F54-435C-83A5-341969CE0190

P698

Q37042128-DF65206E-6BA3-4CF0-8E24-96C65EB2BFA5

P921

Q37042128-6C0AEE62-93EF-41A4-8986-4C6122AB64A1

P932

Q37042128-EB4B8D82-C914-48AD-ABB8-667FF81C1260

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

@en

P2093

Agnes B Fogo

http://www.w3.org/2001/XMLSchema#string

Amber Thompson

http://www.w3.org/2001/XMLSchema#string

Daniel Cattran

http://www.w3.org/2001/XMLSchema#string

Debbie S Gipson

http://www.w3.org/2001/XMLSchema#string

Leslie Powell

http://www.w3.org/2001/XMLSchema#string

Mary Dike

http://www.w3.org/2001/XMLSchema#string

Melanie S Joy

http://www.w3.org/2001/XMLSchema#string

Suzanne Vento

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease

Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450

Mechanism-based concepts of size and maturity in pharmacokinetics.

Emerging evidence of the impact of kidney disease on drug metabolism and transport.

Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma.

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.

P304

39-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.02310508

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey B. Kopp

Howard Trachtman

P577

2008-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19073787

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2615712

http://www.w3.org/2001/XMLSchema#string